Kiniksa Pharmaceuticals, Ltd. Stock price

Equities

KNSA

BMG5269C1010

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
19.73 USD -1.30% Intraday chart for Kiniksa Pharmaceuticals, Ltd. -0.35% +12.49%
Sales 2024 * 383M Sales 2025 * 513M Capitalization 1.39B
Net income 2024 * -10M Net income 2025 * 2M EV / Sales 2024 * 3.02 x
Net cash position 2024 * 236M Net cash position 2025 * 378M EV / Sales 2025 * 1.98 x
P/E ratio 2024 *
-122 x
P/E ratio 2025 *
335 x
Employees 297
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.39%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.30%
1 week-0.35%
Current month-6.67%
1 month-3.09%
3 months+10.53%
6 months+13.26%
Current year+12.49%
More quotes
1 week
19.47
Extreme 19.47
20.32
1 month
19.15
Extreme 19.15
22.09
Current year
17.52
Extreme 17.52
22.09
1 year
10.29
Extreme 10.29
22.09
3 years
7.36
Extreme 7.36
22.09
5 years
5.01
Extreme 5.01
28.67
10 years
5.01
Extreme 5.01
32.88
More quotes
Managers TitleAgeSince
Founder 42 15-06-30
Chief Executive Officer 54 15-06-30
Director of Finance/CFO 50 18-04-30
Members of the board TitleAgeSince
Director/Board Member 55 15-09-30
Director/Board Member 67 15-09-30
Director/Board Member 55 16-11-30
More insiders
Date Price Change Volume
24-03-28 19.73 -1.30% 359,719
24-03-27 19.99 +0.10% 358,398
24-03-26 19.97 +0.05% 406,095
24-03-25 19.96 -0.05% 235,567
24-03-22 19.97 +0.86% 350,736

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
19.73 USD
Average target price
27.8 USD
Spread / Average Target
+40.90%
Consensus
  1. Stock
  2. Equities
  3. Stock Kiniksa Pharmaceuticals, Ltd. - Nasdaq